Skip to main content
SpringerLink
Log in

Opioid Analgesics

Comparative Features and Prescribing Guidelines

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The term ‘opioid’ is a generic term for naturally occurring, semisynthetic and synthetic drugs which combine with opioid receptors to produce physiological effects and which are stereospecifically antagonised by naloxone. For clinical purposes, opioids can be classified according to their receptor interactions (agonist, partial agonist, agonist-antagonist and antagonist), the pain intensity for which they are conventionally used (moderate or severe), and their half-life (short or long). Pure agonists conventionally used for moderate pain, short and long half-life pure agonists conventionally used for severe pain, mixed agonist-antagonists and partial agonist opioids are described in detail. The effective clinical use of opioid drugs requires familiarity with drug selection, routes of administration, dosage guidelines and potential adverse effects. Opioids are unequivocally indicated in the management of severe acute pain and moderate to severe pain associated with cancer. There is increasing acceptance of the role of opioids in the management of recurring acute pain, chronic nonmalignant pain of organic origin and severe neuropathic pain. The selection of opioids is influenced by pain intensity, pharmacokinetic and formulary considerations, previous adverse effects and the presence of coexisting disease. Some patients will require sequential trials of several different opioids before a drug which is effective and well tolerated is identified. Opioid agents should be administered by the most comfortable and convenient route that meets the specific needs of the patient. The regimen for opioid medications should generally provide around-the-clock analgesia with provision for rescue doses for the management of exacerbations of the pain not covered by the regular dosage. At all times, uncontrolled pain should be addressed by gradual increase in the opioid dose until either pain control is achieved or intolerable and unmanageable adverse effects supervene. The management of pain with opioid analgesics demands frequent patient assessment and a readiness to re-evaluate the therapeutic plan in the setting of either inadequate relief or adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, et al., editors. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990: 485–521

    Google Scholar 

  2. Pasternak GW. Pharmacological mechanisms of opioid analgesics. Clin Neuropharmacol 1993; 16(1): 1–18

    PubMed  CAS  Google Scholar 

  3. Knapp RJ, Malatynska E, Collins N, et al. Molecular biology and pharmacology of cloned opioid receptors. FASEB J 1995; 9(7): 516–25

    PubMed  CAS  Google Scholar 

  4. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995; 332(25): 1685–90

    PubMed  CAS  Google Scholar 

  5. Dalsgaard J, Felsby S, Juelsgaard P, et al. Low-dose intra-articular morphine analgesia in day case knee arthroscopy: a randomized double-blinded prospective study. Pain 1994; 56(2): 151–4

    PubMed  CAS  Google Scholar 

  6. Houde RW, Wallenstein SL, Beaver WT. Evaluation of analgesics in patients with cancer pain. In: Lasagna L, editor. International encyclopedia of pharmacology and therapeutics. Vol. 1. New York: Pergamon Press, 1966: 59–67

    Google Scholar 

  7. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990; 43(3): 273–86

    PubMed  CAS  Google Scholar 

  8. World Health Organization. Cancer pain relief. Geneva: World Health Organization, 1986

    Google Scholar 

  9. Chary S, Goughnour BR, Moulin DE, et al. The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain. J Pain Symptom Manage 1994; 9(6): 363–71

    PubMed  CAS  Google Scholar 

  10. Lloyd RS, Costello F, Eves MJ, et al. The efficacy and tolerability of controlled-release dihydrocodeine tablets and combination dextropropoxyphene/paracetamol tablets in patients with severe osteoarthritis of the hips. Curr Med Res Opin 1992; 13(1): 37–48

    PubMed  CAS  Google Scholar 

  11. Pappagallo M, Campbell J. Chronic opioid therapy as an alternative treatment for post herpetic neuralgia. Ann Neurol 1994; 35: S54–56

    PubMed  Google Scholar 

  12. Sunshine A, Olson N, Colon A, et al. Analgesic efficay of controlled release oxycodone vs. immediate release oxycodone alone and in combination with acetaminophen in postoperative pain: a preliminary study. Nida Res Monogr 1993; 132: 329

    Google Scholar 

  13. Zenz M, Strumpf M, Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 1992; 7(2): 69–77

    PubMed  CAS  Google Scholar 

  14. Hopkinson JH. Vicodin, a new analgesic: clinical evaluation of efficacy and safety of repeated doses. Curr Ther Res 1978; 24: 633–45

    Google Scholar 

  15. Poyhia R, Vainio A, Kalso E. A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993; 8(2): 63–7

    PubMed  CAS  Google Scholar 

  16. Inturrisi CE, Colburn WN, Verebey K, et al. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene. Clin Pharmacol Ther 1982; 31: 157–67

    PubMed  CAS  Google Scholar 

  17. De Conno F, Ripamonti C, Sbannotto A, et al. A clinical study on the use of codeine, oxycodone, dextroprpoxyphene, buprenorphine and pentazocine in cancer pain. J Pain Symptom Manage 1991; 6(7): 423–7

    PubMed  Google Scholar 

  18. Raffa RB, Friderichs E, Reimann W, et al. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an ‘atypical’ opioid analgesic. J Pharmacol Exp Ther 1992; 260(1): 275–85

    PubMed  CAS  Google Scholar 

  19. Wilder Smith CH, Schimke J, Osterwalder B, et al. Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol 1994; 5(2): 141–6

    PubMed  CAS  Google Scholar 

  20. Lee CR, McTavish D, Sorkin EM. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993; 46(2): 313–40

    PubMed  CAS  Google Scholar 

  21. Vickers MD, O’Flaherty D, Szekely SM, et al. Tramadol: pain relief by an opioid without depression of respiration. Anaesthesia 1992; 47(4): 291–6

    PubMed  CAS  Google Scholar 

  22. Hoskin PJ, Hanks GW, Aherne GW, et al. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br J Clin Pharmacol 1989; 27(4): 499–505

    PubMed  CAS  Google Scholar 

  23. Westerling D, Frigren L, Hoglund P. Morphine pharmacokinetics and effects on salivation and continuous reaction times in healthy volunteers. Ther Drug Monit 1993; 15(5): 364–74

    PubMed  CAS  Google Scholar 

  24. Davis T, Miser AW, Loprinzi CL, et al. Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer. Hosp J 1993; 9(1): 85–90

    PubMed  CAS  Google Scholar 

  25. Gourlay GK, Plummer JL, Cherry DA, et al. The reproducibility of bioavailability of oral morphine from solution under fed and fasted conditions. J Pain Symptom Manage 1991; 6(7): 431–6

    PubMed  CAS  Google Scholar 

  26. Keefe PA, Merridew CG. 467 consecutive cases of subcutaneous morphine infusions, for palliative care patients [abstract no. 884]. In: 7th World Congress on Pain: Congress Abstracts. Seattle: I.A.S.P. Publications, 1993

    Google Scholar 

  27. Max MB, Inturrisi CE, Kaiko RF, et al. Epidural and intrathecal opiates: cerebrospinal fluid and plasma profiles in patients with chronic cancer pain. Clin Pharmacol Ther 1985; 38: 631–41

    PubMed  CAS  Google Scholar 

  28. Sawe J, Svensson JO, Rane A. Morphine metabolism in cancer patients on increasing oral doses — no evidence for autoinduction or dose dependence. J Clin Pharmacol 1983; 16: 85–93

    CAS  Google Scholar 

  29. Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide — a potent antagonist of morphine analgesia. Life Science 1990; 47: 579–85

    CAS  Google Scholar 

  30. Ashby MA, Flemming BG, van Crugten J, et al. Plasma morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) concentrations in hospice patients recieving morphine for cancer pain: absence of relationship to opioid side effects [abstract no. 1002]. In: 7th World Congress on Pain: Abstracts. Seattle: I.A.S.P. Publications, 1993

    Google Scholar 

  31. Bowsher D. Paradoxical pain [editorial]. BMJ 1993; 306: 473

    PubMed  CAS  Google Scholar 

  32. Jacobsen LS, Olsen AK, Sjogren P, et al. Morphine-induced hyperalgesia, allodynia and myoclonus — new side-effects of morphine? [in Danish]. Ugeskr Laeger 1995; 157(23): 3307–10

    PubMed  CAS  Google Scholar 

  33. Paul D, Standifer KM, Inturrisi CE, et al. Pharmacological characterization of morphine-6 beta-glucuronide, a very potent morphine metabolite. J Pharmacol Exp Ther 1989; 251(2): 477–83

    PubMed  CAS  Google Scholar 

  34. Pasternak GW, Bodnar RJ, Clarke JA, et al. Morphine-6-glucuronide, a potent Mu agonist. Life Science 1987; 41: 2845–9

    CAS  Google Scholar 

  35. Shimomura K, Kamata O, Ueki S, et al. Analgesic effects of morphine glucuronides. Tohoku J Exp Med 1971; 105: 45–51

    PubMed  CAS  Google Scholar 

  36. Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J Clin Res Ed 1986; 292: 1548–9

    PubMed  CAS  Google Scholar 

  37. Hanna MH, Peat SJ, Woodham M, et al. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth 1990; 64(5): 547–50

    PubMed  CAS  Google Scholar 

  38. Osbome R, Thompson P, Joel S, et al. The analgesic activity of morphine-6-glucuronide. Br J Clin Pharmacol 1992; 34(2): 130–8

    Google Scholar 

  39. Portenoy RK, Thaler HT, Inturrisi CE, et al. The metabolite, morphine-6-glucuronide, contributes to the analgesia produced by morphine infusion in pain patients with normal renal function. Clin Pharmacol Ther 1992; 51(4): 422–31

    PubMed  CAS  Google Scholar 

  40. D’Honneur G, Gilton A, Sandouk P, et al. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine: the influence of renal failure. Anesthesiology 1994; 81(1): 87–93

    PubMed  Google Scholar 

  41. Hagen N, Foley KM, Cerbones DJ, et al. Chronic nausea and morphine-6-glucuronide. J Pain Sympt Manage 1991; 6: 125–8

    CAS  Google Scholar 

  42. Lehmann KA, Zech D. Morphine-6-glucuronide, a pharmacologically active morphine metabolite: a review of the literature. Eur J Pain 1993; 12(2): 28–35

    Google Scholar 

  43. Houde RW, Wallenstein SL, Beaver WT. Clinical measurement of pain. In: de Stevens G, editor. Analgesics. New York: Academic Press, 1965: 75–122

    Google Scholar 

  44. Hasselstrom J, Eriksson LS, Persson A, et al. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990; 29: 289–97

    PubMed  CAS  Google Scholar 

  45. Sawe J, Dahlstrom B, Paazlow L, et al. Morphine kinetics in cancer patients. Clin Pharmacol Ther 1981; 30: 629–34

    PubMed  CAS  Google Scholar 

  46. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47(5): 639–46

    PubMed  CAS  Google Scholar 

  47. Kaiko RF. Commentary: equianalgesic dose ratio of intramuscular/oral morphine, 1: 6 versus 1: 3. In: Foley KM, Inturrisi CE, editors. Opioid analgesics in the management of clinical pain: advances in pain research and therapy. Vol. 8. New York: Raven Press, 1986: 87–94

    Google Scholar 

  48. Twycross RG. Opioid analgesics in cancer pain: current practice and controversies. Cancer Surv 1988; 7(1): 29–53

    PubMed  CAS  Google Scholar 

  49. Ferrell B, Wisdom C, Wenzl C, et al. Effects of controlled-released morphine on quality of life for cancer pain. Oncol Nurs Forum 1989; 16(4): 521–6

    PubMed  CAS  Google Scholar 

  50. Forman WB, Portenoy RK, Yanagihara RH, et al. A novel morphine sulphate preparation: clinical trial of a controlled-release morphine suspension in cancer pain. Palliat Med 1993; 7(4): 301–6

    PubMed  CAS  Google Scholar 

  51. Babul N, Darke AC, Anslow JA, et al. Pharmacokinetics of two novel rectal controlled-release morphine formulations. J Pain Symptom Manage 1992; 7(7): 400–5

    PubMed  CAS  Google Scholar 

  52. Inturrisi CE, Max MB, Foley KM, et al. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 1984; 310: 1213–7

    PubMed  CAS  Google Scholar 

  53. Kaiko RF, Wallenstein SL, Rogers AG, et al. Analgesic and mood effects of heroin and morphine in cancer patients with postoperative pain. N Engl J Med 1981; 304: 1501–5

    PubMed  CAS  Google Scholar 

  54. Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1977; 86(6): 738–41

    PubMed  CAS  Google Scholar 

  55. Eisendrath SJ, Goldman B, Douglas J, et al. Meperidine-induced delirium. Am J Psychiatry 1987; 144(8): 1062–5

    PubMed  CAS  Google Scholar 

  56. Hagmeyer KO, Mauro LS, Mauro VF. Meperidine-related seizures associated with patient-controlled analgesia pumps. Ann Pharmacother 1993; 27(1): 29–32

    PubMed  CAS  Google Scholar 

  57. Umans JG, Inturrisi CE. Antinociceptive activity and toxicity of meperidine and normeperidine in mice. J Pharmacol Exp Ther 1982; 223: 203–6

    PubMed  CAS  Google Scholar 

  58. Kaiko RF, Foley KM, Grabinski PV, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13: 180–5

    PubMed  CAS  Google Scholar 

  59. Agency for Health Care Policy and Research: Acute Pain Management Panel. Acute pain management: operative or medical procedures and trauma. Clinical practice guideline. Washington: US Department of Health and Human Services, 1992

    Google Scholar 

  60. Houde RW. Clinical analgesic studies of hydromorphone. In: Foley KM, Inturrisi CE, editors. Opioid analgesics in the management of clinical pain. Advances in pain research and therapy. Vol. 8. New York: Raven Press, 1986: 129–36

    Google Scholar 

  61. Moulin DE, Kreeft JH, Murray PN, et al. Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain. Lancet 1991; 337: 465–8

    PubMed  CAS  Google Scholar 

  62. Hays H, Hagen N, Thirlwell M, et al. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer 1994; 74(6): 1808–6

    PubMed  CAS  Google Scholar 

  63. Brose WG, Tanalian DL, Brodsky JB, et al. CSF and blood pharmacokinetics of hydromorphone and morphine following lumbar epidural administration. Pain 1991; 45: 11–7

    PubMed  CAS  Google Scholar 

  64. Leow KP, Smith MT, Williams B, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52(5): 487–95

    PubMed  CAS  Google Scholar 

  65. Glare PA, Walsh TD. Dose-ranging study of oxycodone for chronic pain in advanced cancer. J Clin Oncol 1993; 11(5): 973–8

    PubMed  CAS  Google Scholar 

  66. Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 1995; 80(2): 296–302

    PubMed  CAS  Google Scholar 

  67. Sinatra RS, Hyde NH, Harrison DM. Oxymorphone revisited. Semin Anesth 1988; 8(3): 208–15

    Google Scholar 

  68. Hermens JM, Hanifin JM, Hirshman CA. Comparison of histamine release in human skin mast cells by morphine, fentanyl and oxymorphone. Anesthesiology 1985; 62: 124–9

    PubMed  CAS  Google Scholar 

  69. Varvel JR, Shafer SL, Hwang SS, et al. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989; 70: 928–34

    PubMed  CAS  Google Scholar 

  70. Gourlay GK, Kowalski SR, Plummer JL, et al. The efficacy of transdermal fentanyl in the treatment of postoperative pain; a double blind comparison of fentanyl and placebo systems. Pain 1990; 40: 21–8

    PubMed  CAS  Google Scholar 

  71. Calis KA, Kohler DR, Corso DM. Transdermally administered fentanyl for pain management. Clin Pharmacol 1992; 11(1): 22–36

    CAS  Google Scholar 

  72. Fine PG, Marcus M, DeBoer AJ, et al. An open label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough cancer pain. Pain 1991; 45: 149–55

    PubMed  CAS  Google Scholar 

  73. Singer M, Noonan KR. Continuous intravenous infusion of fentanyl: case reports of use in patients with advanced cancer and intractable pain. J Pain Symptom Manage 1993; 8(4): 215–20

    PubMed  CAS  Google Scholar 

  74. Holley FO, Van-Steennis C. Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constantrate IV and transdermal delivery. Br J Anaesth 1988; 60: 608–13

    PubMed  CAS  Google Scholar 

  75. Portenoy PK, Southam M, Gupta SK, et al. Transdermal fentanyl for cancer pain repeated dose pharmacokinetics. Anesthesiology 1993; 78: 36–43

    PubMed  CAS  Google Scholar 

  76. Willens JS, Myslinski NR. Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil [published erratum appears in Heart Lung 1993 Jul–Aug; 22 (4): 307]. Heart Lung 1993; 22(3): 239–51

    PubMed  CAS  Google Scholar 

  77. Hopton D. Double-blind clinical trial of the analgesic effects of phenazocine hydrobromide (Narphen) compared with morphine sulphate in patients with acute abdominal pain. Gut 1971; 12(1): 51–4

    PubMed  CAS  Google Scholar 

  78. Brown AS. Absorption of analgesics from the buccal mucous membrane. Practitioner 1966; 196(171): 125–6

    PubMed  CAS  Google Scholar 

  79. Ventafridda V, Ripamonti C, Bianchi M, et al. A randomized study on oral administration of morphine and methadone in the treatment of cancer pain. J Pain Symptom Manage 1986; 1(4): 203–8

    PubMed  CAS  Google Scholar 

  80. Twycross RG, Lack SA. Symptom control in far-advanced cancer. In: Twycross RG, Lack SA, editors. Pain relief. London: Pitman, 1984

    Google Scholar 

  81. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993; 52(2): 137–47

    PubMed  CAS  Google Scholar 

  82. Sawe J, Hansen J, Ginman C, et al. Patient-controlled dose regimen of methadone for chronic cancer pain. BMJ 1981; 282(6266): 771–3

    PubMed  CAS  Google Scholar 

  83. Grochow L, Sheidler V, Grossman S, et al. Does intravenous methadone provide longer lasting analgesia than intravenous morphine? A randomized double-blind study. Pain 1989; 38(2): 151–7

    PubMed  CAS  Google Scholar 

  84. Bruera E, Fainsinger R, Moore M, et al. Local toxicity with subcutaneous methadone: experience of two centers. Pain 1991; 45: 141–5

    PubMed  CAS  Google Scholar 

  85. Dixon R, Crews T, Inturrisi CE, et al. Levorphanol: pharmacokinetics and steady-state plasma concentrations in patients with pain. Res Commun Chem Pathol Pharmacol 1983; 41: 3–17

    PubMed  CAS  Google Scholar 

  86. Wallenstein SL, Rogers AG, Kaiko RF, et al. Clinical analgesic studies of levorphanol in acute and chronic cancer pain. In: Foley KM, Inturrisi CE, editors. Opioid analgesics in the management of clinical pain: advances in pain research and therapy. Vol. 8. New York: Raven Press, 1986: 211–5

    Google Scholar 

  87. Moulin DE, Ling GS, Pasternak GW. Unidirectional cross tolerance between morphine and levorphanol in the rat. Pain 1988; 33: 233–9

    PubMed  CAS  Google Scholar 

  88. Houde RW. Analgesic effectiveness of narcotic agonist-antagonists. Br J Clin Pharmacol 1979; 7: 297–308

    CAS  Google Scholar 

  89. Wallenstein SL, Rogers AG, Kaiko RF, et al. Crossover trials in clinical analgesic assays: studies of buprenorphine and morphine. Pharmacotherapy 1986; 6: 228–35

    PubMed  CAS  Google Scholar 

  90. Bullingham R, McQuay H, Porter E, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982; 13: 665–73

    PubMed  CAS  Google Scholar 

  91. Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression, Clin Pharmacol Ther 1989; 45: 66–71

    PubMed  CAS  Google Scholar 

  92. Beaver W, Wallenstein S, Houde R, et al. Comparison of the analgesic effects of pentazocine and morphine in patients with cancer. Clin Pharmacol Ther 1966; 7: 740–51

    PubMed  CAS  Google Scholar 

  93. Woods AJJ, Moir DC, Campbell C, et al. Medicines monitoring and evaluation group: central nervous system effects of pentazocine. BMJ 1974; 1: 304–7

    Google Scholar 

  94. Caruso FS. Butorphanol: clinical analgesic studies. In: Foley K, Inturrisi C, editors. Opioid analgesics in the management of clinical pain: advances in pain research and therapy. Vol. 8. New York: Raven Press, 1986: 253–7

    Google Scholar 

  95. Gillis JC, Benfield P, Goa KL. Transnasal butorphanol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute pain management. Drugs 1995 Jul; 50(1): 157–75

    PubMed  CAS  Google Scholar 

  96. Ralley FE. Intranasal opiates: old route for new drugs. Can J Anaesth 1989; 36(5): 491–3

    PubMed  CAS  Google Scholar 

  97. Hoffert MJ, Couch JR, Diamond S, et al. Transnasal butorphanol in the treatment of acute migraine. Headache 1995; 35(2): 65–9

    PubMed  CAS  Google Scholar 

  98. Baumel B. Migraine: a pharmacologic review with newer options and delivery modalities. Neurology 1994 May; 44 (5 Suppl. 3): S13–7

    PubMed  CAS  Google Scholar 

  99. Joyce T, Kubicek MF, Skjonsby BS, et al. Efficacy of transnasal butorphanol tartrate in postepisiotomy pain: a model to assess analgesia. Clin Ther 1993; 15(1): 160–7

    PubMed  Google Scholar 

  100. Scott JL, Smith MS, Sanford SM, et al. Effectiveness of transnasal butorphanol for the treatment of musculoskeletal pain. Am J Emerg Med 1994; 12(4): 469–71

    PubMed  CAS  Google Scholar 

  101. Agency for Health Care Policy and Research: Cancer Pain Management Panel. Management of cancer pain. Clinical practice guideline no. 9. Washington: US Department of Health and Human Services, 1994

    Google Scholar 

  102. Brookoff D, Polomano R. Treating sickle cell pain like cancer pain. Ann Intern Med 1992; 116(5): 364–8

    PubMed  CAS  Google Scholar 

  103. Ziegler DK. Opiate and opioid use in patients with refractory headache. Cephalalgia 1994; 14(1): 5–10

    PubMed  CAS  Google Scholar 

  104. Markley HG. Chronic headache: appropriate use of opiate analgesics. Neurology 1994; 44 Suppl. 3: 18–24

    Google Scholar 

  105. Jamison RN, Anderson KO, Peeters AC, et al. Survey of opioid use in chronic nonmalignant pain patients. Reg Anesth 1994; 19(4): 225–30

    PubMed  CAS  Google Scholar 

  106. Reidenberg MM, Portenoy RK. The need for an open mind about the treatment of chronic nonmalignant pain. Clin Pharmacol Ther 1994; 55(4): 367–9

    PubMed  CAS  Google Scholar 

  107. Schofferman J. Long-term use of opioid analgesics for the treatment of chronic pain of nonmalignant origin. J Pain Symptom Manage 1993; 8(5): 279–88

    PubMed  CAS  Google Scholar 

  108. Hill CJ. The intractable pain treatment act of Texas. Tex Med 1992; 88(2): 70–2

    PubMed  Google Scholar 

  109. Hampf GB, Kalso EA. Chronic use of opioids in intractable facial pain: a case report. Acta Odontol Scand 1991; 49(4): 215–8

    PubMed  CAS  Google Scholar 

  110. Tennant FJ, Robinson D, Sagherian A, et al. Chronic opioid treatment of intractable, non-malignant pain. Nida Res Monogr 1988; 81(1): 174–80

    PubMed  Google Scholar 

  111. Portenoy RK, Farkash A. Practical management of non-malignant pain in the elderly. Geriatrics 1988; 43(5): 29–40

    PubMed  CAS  Google Scholar 

  112. Gonzales GR, Portenoy RK. Selection of analgesic therapies in rheumatoid arthritis: the role of opioid medications. Arthritis Care Res 1993; 6(4): 223–8

    PubMed  CAS  Google Scholar 

  113. Devor M, Basbaum AI, Bennett GJ, et al. Group report: mechanisms of neuropathic pain following peripheral injury. In: Basbaum A, Besson J-M, editors. Towards a new pharmacotherapy of pain. New York: John Wiley & Sons, 1991: 417–40

    Google Scholar 

  114. Portenoy RK. Issues in the management of neuropathic pain. In: Basbaum A, Besson J-M, editors. Towards a new pharmacotherapy of pain. New York: John Wiley & Sons, 1991: 393–416

    Google Scholar 

  115. Rowbotham MC, Reisner L, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41(7): 1024–8

    PubMed  CAS  Google Scholar 

  116. Jadad AR, Carroll D, Glynn CJ, et al. Morphine responsiveness of chronic pain: double blind randomised crossover study with patient controlled analgesia. Lancet 1992; 339: 1367–71

    PubMed  CAS  Google Scholar 

  117. McQuay HJ, Jadad AR, Carroll D, et al. Opioid sensitivity of chronic pain: a patient controlled analgesia method. Anaesthesia 1992; 47: 757–67

    PubMed  CAS  Google Scholar 

  118. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33(1): 11–23

    PubMed  CAS  Google Scholar 

  119. Dubner R. A call for more science, not more rhetoric, regarding opioids and neuropathic pain [editorial]. Pain 1991; 47(1): 1–2

    PubMed  CAS  Google Scholar 

  120. Cherny NI, Thaler HT, Friedlander-Klar H, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled single dose studies. Neurology 1994; 44: 857–61

    PubMed  CAS  Google Scholar 

  121. Portenoy RK. Adjuvant analgesics in pain management. In: Doyle D, Hanks GW, MacDonald N, editors. Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1993: 187–203

    Google Scholar 

  122. World Health Organization. Cancer pain relief and palliative care. Geneva: World Health Organization, 1990

    Google Scholar 

  123. Galer BS, Coyle N, Pasternak GW, et al. Individual variability in the response to different opioids: report of five cases. Pain 1992; 49(1): 87–91

    PubMed  CAS  Google Scholar 

  124. de Stoutz ND, Bruera E, Suarez Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10(5): 378–84

    PubMed  Google Scholar 

  125. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain: case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer 1993; 72(7): 2266–72

    PubMed  CAS  Google Scholar 

  126. MacDonald N, Der L, Allan S, et al. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 1993; 53(3): 353–5

    PubMed  CAS  Google Scholar 

  127. Leng G, Finnegan MJ. Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat Med 1994; 8(2): 153–5

    PubMed  CAS  Google Scholar 

  128. Cherny NI, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995; 76: 1283–93

    PubMed  CAS  Google Scholar 

  129. Chan GL, Matzke GR. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 1987; 21(10): 773–83

    PubMed  CAS  Google Scholar 

  130. Sawe J, Svensson JO, Odar-Cederlof I. Kinetics of morphine in patients with renal failure [letter]. Lancet 1985; 2: 211

    PubMed  CAS  Google Scholar 

  131. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady state concentrations and the consequences of renal failure. Pain 1991; 47: 13–9

    PubMed  CAS  Google Scholar 

  132. McQuay HJ, Carroll D, Faura CC, et al. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48(3): 236–44

    PubMed  CAS  Google Scholar 

  133. Beaver WT, Feise G. Comparison of the analgesic effect oxymorphone by rectal suppository and intramuscular injection in patients with postoperative pain. J Clin Pharmacol 1977; 17: 276

    PubMed  CAS  Google Scholar 

  134. Hanning CD. The rectal absorption of opioids. In: Benedetti C, Chapman CR, Giron G, editors. Opioid analgesia in the management of clinical pain: advances in pain research and therapy. Vol. 14. New York: Raven Press, 1990: 259–69

    Google Scholar 

  135. Hanning CD, Vickers AP, Smith G, et al. The morphine hydrogel suppository: a new sustained release preparation. Br J Anaesth 1988; 61: 221–7

    PubMed  CAS  Google Scholar 

  136. Wilkinson TJ, Robinson BA, Begg EJ, et al. Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. Cancer Chemother Pharmacol 1992; 31(3): 251–4

    PubMed  CAS  Google Scholar 

  137. Korte W, Morant R. Transdermal fentanyl in uncontrolled cancer pain: titration on a day-to-day basis as a procedure for safe and effective dose finding — a pilot study in 20 patients. Support Care Cancer 1994; 2(2): 123–7

    PubMed  CAS  Google Scholar 

  138. Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharm Ther 1988; 44: 335–42

    CAS  Google Scholar 

  139. Carl P, Crawford ME, Madsen NB, et al. Pain relief after major abdominal surgery: a double-blind controlled comparison of sublingual buprenorphine, intramuscular buprenorphine, and intramuscular meperidine. Anesth Analg 1987; 66(2): 142–6

    PubMed  CAS  Google Scholar 

  140. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75(2): 223–9

    PubMed  CAS  Google Scholar 

  141. Shyu WC, Pittman KA, Robinson D, et al. Multiple-dose phase I study of transnasal butorphanol. Clin Pharmacol Ther 1993; 54(1): 34–41

    PubMed  CAS  Google Scholar 

  142. Coyle N, Cherny NI, Portenoy RK. Subcutaneous opioid infusions in the home. Oncology 1994; 8(4): 21–7

    PubMed  CAS  Google Scholar 

  143. Bruera E, Brenneis C, Michaud M, et al. Use of the subcutaneous route for the administration of narcotics in patients with cancer pain. Cancer 1988; 62(2): 407–11

    PubMed  CAS  Google Scholar 

  144. Storey P, Hill HH, St Louis R, et al. Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage 1990; 5: 33–41

    PubMed  CAS  Google Scholar 

  145. Portenoy RK. Continuous intravenous infusions of opioid drugs. Med Clin North Am 1987; 71: 233–41

    PubMed  CAS  Google Scholar 

  146. Dover SB. Syringe driver in terminal care. BMJ 1987; 294: 553–5

    PubMed  CAS  Google Scholar 

  147. Amesbury BDW. Use of SC midazolam in the home care setting. Palliat Med 1989; 3: 299–301

    Google Scholar 

  148. Oliver DJ. Syringe drivers in palliative care: a review. Palliat Med 1988; 2: 21–6

    Google Scholar 

  149. Trissel LA, Xu Q, Martinez JF, et al. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22, and 32 degrees C. Am J Hosp Pharm 1994; 51(17): 2138–42

    PubMed  CAS  Google Scholar 

  150. Lichter I, Hunt E. Drug combinations in syringe drivers. NZ Med J 1995; 108(1001): 224–6

    CAS  Google Scholar 

  151. Waldmann CS, Eason JR, Rambohu IE, et al. Serum morphine levels: a comparison between continuous subcutaneous infusions and intravenous infusions in postoperative patients. Anesthesia 1984; 39(8): 768–71

    CAS  Google Scholar 

  152. Yaksh TL, Reddy SVR. Studies in the primate on the analgesic effects associated with intrathecal actions of opiates, alpha adrenergic agonists and baclofen. Anesthesiology 1981; 54: 451–67

    PubMed  CAS  Google Scholar 

  153. Yaksh TL. Spinal opiate analgesics: characteristics and principal action. Pain 1981; 11: 293–346

    PubMed  CAS  Google Scholar 

  154. Moulin DE, Inturrisi CE, Foley KM. Epidural and intrathecal opioids: cerebrospinal fluid and plasma pharmacokinetics in cancer pain patients. In: Foley KM, Inturrisi CE, editors. Opioid analgesics in the management of clinical pain: advances in pain research and therapy. Vol. 8. New York: Raven Press, 1986: 369–84

    Google Scholar 

  155. Chrubasik J, Wust H, Schulte MJ, et al. Relative analgesic potency of epidural fentanyl, alfentanil, and morphine in treatment of postoperative pain. Anesthesiology 1988; 68: 929–33

    PubMed  CAS  Google Scholar 

  156. Du Pen S, Kharasch ED, Williams A, et al. Chronic epidural bupivacaine-opioid infusion in intractable cancer pain. Pain 1992; 49(3): 293–300

    PubMed  Google Scholar 

  157. Nitescu P, Appelgren L, Linder LE, et al. Epidural versus intrathecal morphine-bupivicaine: assessment of consecutive treatment in advanced cancer pain. J Pain Symptom Manage 1990; 5: 18–26

    PubMed  CAS  Google Scholar 

  158. Hogan Q, Haddox JD, Abram S, et al. Epidural opiates and local anesthetics for the management of cancer pain. Pain 1991; 46(3): 271–9

    PubMed  CAS  Google Scholar 

  159. Sjoberg M, Appelgren L, Einarsson S, et al. Long-term intrathecal morphine and bupivacaine in ‘refractory’ cancer pain: results from the first series of 52 patients. Acta Anaesthesiol Scand 1991; 35(1): 30–43

    PubMed  CAS  Google Scholar 

  160. Van Dongen RT, Crul BJ, De Bock M. Long-term intrathecal infusion of morphine and morphine/bupivacaine mixtures in the treatment of cancer pain: a retrospective analysis of 51 cases. Pain 1993; 55(1): 119–23

    PubMed  Google Scholar 

  161. Sjoberg M, Nitescu P, Appelgren L, et al. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain: results from a morphine/bupivacaine dose regimen of 0.5/4.75 mg/ml. Anesthesiology 1994; 80(2): 284–97

    PubMed  CAS  Google Scholar 

  162. Crul BJ, van Dongen RT, Snijdelaar DG, et al. Long-term continuous intrathecal administration of morphine and bupivacaine at the upper cervical level: access by a lateral C1-C2 approach. Anesth Analg 1994; 79(3): 594–7

    PubMed  CAS  Google Scholar 

  163. Goucke R. Continuous intrathecal analgesia with opioid/local anaesthetic mixture for cancer pain. Anaesth Intens Care 1993; 21(2): 222–3

    CAS  Google Scholar 

  164. Obbens EAMT, Hill CS, Leavens ME, et al. Intraventricular morphine administration for control of chronic cancer pain. Pain 1987; 28: 61–8

    PubMed  CAS  Google Scholar 

  165. Lobato RD, Madrid JL, Fatela LV, et al. Intraventricular morphine for intractable cancer pain: rationale, methods, clinical results. Acta Anaesthesiol Scand 1987; 31 Suppl.: 68–74

    Google Scholar 

  166. Leavens ES, Hill CS, Cech DA, et al. Intrathecal and intraventricular morphine for pain in cancer patients. J Neurosurg 1982; 56: 241–5

    PubMed  CAS  Google Scholar 

  167. Lee TL, Kumar A, Baratham G. Intraventricular morphine for intractable craniofacial pain. Singapore Med J 1990; 31(3): 273–6

    PubMed  CAS  Google Scholar 

  168. Nurchi G. Use of intraventricular and intrathecal morphine in intractable pain associated with cancer. Neurosurgery 1984; 15(6): 801–4

    PubMed  CAS  Google Scholar 

  169. Roquefeil B, Benezich J, Blanchet P, et al. Intraventricular administration of morphine in patients with neoplastic intractable pain. Surg Neurol 1984; 21: 155–8

    Google Scholar 

  170. Crammond T, Stuart G. Intraventricular morphine for intractable pain of advanced cancer. J Pain Symptom Manage 1993; 8(7): 465–73

    Google Scholar 

  171. Dennis GC, DeWitty RL. Long-term intraventricular infusion of morphine for intractable pain in cancer of the head and neck. Neurosurgery 1990; 26: 404–7

    PubMed  CAS  Google Scholar 

  172. Bruera E, Sloan P, Scott J, et al. Slow release (SR) versus intermediate release (IR) hydromorphone (HM) in patients with cancer pain: a controlled, crossover trial [abstract no. 899]. 7th World Congress on Pain: congress abstracts. Seattle: I.A.S.P. Publications, 1993

    Google Scholar 

  173. Thomas Z, Bruera E. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manage 1995; 10(4): 315–7

    PubMed  CAS  Google Scholar 

  174. Brescia FJ, Portenoy RK, Ryan M, et al. Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 1992; 10(1): 149–55

    PubMed  CAS  Google Scholar 

  175. Kanner RM, Foley KM. Patterns of narcotic drug use in a cancer pain clinic. Ann NY Acad Sci 1981; 362: 161–72

    PubMed  CAS  Google Scholar 

  176. Coyle N, Adelhardt J, Foley KM, et al. Character of terminal illness in the advanced cancer patient: pain and other symptoms during last four weeks of life. J Pain Symptom Manage 1990; 5: 83–9

    PubMed  CAS  Google Scholar 

  177. Lichter I. Accelerated titration of morphine for rapid relief of cancer pain. NZ Med J 1994; 107(990): 488–90

    CAS  Google Scholar 

  178. Edwards WT, Breed RJ. Treatment of postoperative pain in the post anesthesia care unit. Anesthesiol Clin North Am 1990; 8: 235–65

    Google Scholar 

  179. Portenoy RK. Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med Singapore 1994; 23(2): 160–70

    PubMed  CAS  Google Scholar 

  180. Sykes NP. Oral naloxone in opioid associated constipation. Lancet 1991; 337: 1475

    PubMed  CAS  Google Scholar 

  181. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, et al. Treatment of opioid induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1992; 52: 90–5

    PubMed  CAS  Google Scholar 

  182. Campora E, Merlini L, Pace M, et al. The incidence of narcotic induced emesis. J Pain Symptom Manage 1991; 6(7): 428–30

    PubMed  CAS  Google Scholar 

  183. Cole RM, Robinson F, Harvey L, et al. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J Pain Symptom Manage 1994; 9(1): 48–50

    PubMed  CAS  Google Scholar 

  184. Bruera E, Brenneis C, Paterson AH, et al. Use of methylphenedate as an adjuvant to narcotic analgesics in patients with advanced cancer. J Pain Symptom Manage 1989; 4: 3–6

    PubMed  CAS  Google Scholar 

  185. Bruera E, Chadwick S, Brenneis C, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71: 67–70

    PubMed  CAS  Google Scholar 

  186. Forrest WH, Brown BW, Brown CR, et al. Dextroamphetamine with morphine for the treatment of postoperative pain. N Engl J Med 1977; 296: 712–5

    PubMed  Google Scholar 

  187. Breitbart W, Mermelstein H. Pemoline: an alternative psychostimulant for the management of depressive disorders in cancer patients. Psychosomatics 1992; 33(3): 352–6

    PubMed  CAS  Google Scholar 

  188. Fainsinger R, Tapper M, Bruera E. A perspective on the management of delirium in terminally ill patients on a palliative care unit. J Palliat Care 1993; 9(3): 4–8

    PubMed  CAS  Google Scholar 

  189. Foley KM. Clinical tolerance to opioids. In: Basbaum AI, Bessom JM, editor. Towards a new pharmacotherapy of pain, Dahlem Konfrenzen. Chichester: John Wiley & Sons, 1991: 181–204

    Google Scholar 

  190. Hanks GW, Twycross RG, Lloyd JW. Unexpected complication of successful nerve block: morphine induced respiratory depression precipitated by removal of severe pain. Anaesthesia 1981; 36(1): 37–9

    PubMed  CAS  Google Scholar 

  191. Goldfrank L, Weisman RS, Errick JK, et al. A dosing nomogram for continuous infusion of intravenous naloxone. Ann Emerg Med 1986; 15(5): 91–5

    Google Scholar 

  192. Bradberry JC, Reabel MA. Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intel Clin Pharm 1981; 15: 85–90

    Google Scholar 

  193. Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59(2): 313–6

    PubMed  CAS  Google Scholar 

  194. Eisele JH, Grigsby EJ, Dea G. Clonazepam treatment of myoclonic contractions associated with high dose opioids: a case report. Pain 1992; 49(2): 231–2

    PubMed  Google Scholar 

  195. Mercadante S. Dantrolene treatment of opioid-induced myoclonus. Anesth Analg 1995; 81(6): 1307–8

    PubMed  CAS  Google Scholar 

  196. Schuster CR. Does treatment of cancer pain with narcotics produce junkies? In: Hill CS, Fields WS, editors. Drug treatment of cancer pain in a drug-oriented society: advances in pain research and therapy. Vol. 11. New York: Raven Press, 1989: 1–3

    Google Scholar 

  197. Cleeland CS. Pain control: public and physicians’ attitudes. In: Hill CS, Fields WS, editors. Drug treatment of cancer pain in a drug-oriented society: advances in pain research and therapy. Vol. 11. New York: Raven Press, 1989: 81–9

    Google Scholar 

  198. Foley KM. The decriminalization of cancer pain. In: Hill CS, Fields WS, editors. Drug treatment of cancer pain in a drug-oriented society: advances in pain research and therapy. Vol. 11. New York: Raven Press, 1989: 5–18

    Google Scholar 

  199. Chapman CR, Hill HF. Prolonged morphine self-administration and addiction liability. Cancer 1989; 63: 1636–44

    PubMed  CAS  Google Scholar 

  200. Foley KM. Controversies in cancer pain: medical perspective. Cancer 1989; 63: 2257–65

    PubMed  CAS  Google Scholar 

  201. Porter J, Jick H. Addiction rare in patients treated with narcotics [letter]. N Engl J Med 1980; 302: 123

    PubMed  CAS  Google Scholar 

  202. Perry S, Heidrich G. Management of pain during debridement: a survey of US burn centers. Pain 1982; 13: 267–80

    PubMed  CAS  Google Scholar 

  203. Chapman CR. Giving the patient control of opioid analgesic administration. In: Hill CS, Fields WS, editors. Drug treatment of cancer pain in a drug-oriented society: advances in pain research and therapy. Vol. 11. New York: Raven Press, 1989: 339–51

    Google Scholar 

  204. American College of Physicians Health and Public Policy Committee. Drug therapy for severe chronic pain in terminal illness. Ann Intern Med 1983; 99: 870–80

    Google Scholar 

  205. American Pain Society. Principles of analgesic use in the treatment acute pain and chronic cancer pain: a concise guide to medical practice. 3rd ed. Skokie (IL): American Pain Society, 1992

    Google Scholar 

  206. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84–95

    PubMed  CAS  Google Scholar 

  207. Hill CS, Fields WS, editors. Drug treatment of cancer pain in a drug oriented society: advances in pain research and therapy. Vol. 11. New York: Raven Press, 1989

    Google Scholar 

  208. Inturrisi CE. Management of cancer pain. Cancer 1989; 63: 2308–20

    PubMed  CAS  Google Scholar 

  209. Walsh TD. Prevention of opioid side effects. J Pain Symptom Manage 1990; 5(6): 363–7

    Google Scholar 

  210. Weissman DE, Haddox JD. Opioid pseudoaddiction — an iatrogenic syndrome. Pain 1989; 36: 363–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Pain and Palliative Medicine, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel, 91031

    Nathan I. Cherny (Clinical Coordinator)

Authors
  1. Nathan I. Cherny
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cherny, N.I. Opioid Analgesics. Drugs 51, 713–737 (1996). https://doi.org/10.2165/00003495-199651050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199651050-00002

Keywords

Search

Navigation